Please login to the form below

Not currently logged in

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

Johnson and Johnson logo Johnson & Johnson has acquired California-based clinical stage biopharma company Alios BioPharma for $1.75bn.

The deal will give it access to a portfolio of potential therapeutics for viral infections, including the orally administered AL-8176.

The antiviral therapy has the potential to be first-in-class and is currently in phase II studies as a treatment for respiratory syncytial virus (RSV) in infants.

William Hait, global head of research and development for Janssen Pharmaceutical Companies of Johnson & Johnson, said: “We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major paediatric diseases with no available preventive therapy.

“AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five,” he added.

The acquisition will include Alios BioPharma's preclinical programmes that target influenza and rhinovirus, as well as RSV.

Johan Van Hoof, global head of infectious diseases and vaccines at Janssen, said: “Alios BioPharma's pipeline is closely aligned with our vision to continue to address important unmet medical needs through scientific innovation.

“This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide.”

The deal is expected to be finalised by the end of the year. 

Article by
Kirstie Pickering

1st October 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....